Clinical Report: Severe Autoimmune Hemolytic Anemia Triggered by Pembrolizumab
Overview
This case report details a 52-year-old female with malignant melanoma who developed severe autoimmune hemolytic anemia (AIHA) following pembrolizumab treatment. An innovative immunosuppressive approach involving cyclophosphamide and fluorouracil was effective in managing her condition, allowing for safe rechallenge with pembrolizumab.
Background
Immune checkpoint inhibitors (ICIs) like pembrolizumab have significantly improved survival rates in melanoma patients, but they can cause severe immune-related adverse events (irAEs). Autoimmune hemolytic anemia (AIHA) is a rare but serious complication that can arise from ICI therapy, necessitating prompt recognition and management. Understanding the treatment options for AIHA is crucial for optimizing patient outcomes while continuing effective cancer therapies.
Data Highlights
No numerical data available in the article.
Key Findings
A 52-year-old female developed severe AIHA after one cycle of pembrolizumab.
Initial treatment with corticosteroids and IVIG was insufficient to control hemolysis.
Combination therapy with cyclophosphamide and fluorouracil alongside corticosteroids effectively managed the severe AIHA.
After three months, the patient was safely rechallenged with pembrolizumab, managing subsequent AIHA with corticosteroids alone.
This case highlights the need for innovative treatment strategies for severe AIHA associated with ICIs.
Further research is needed to validate the efficacy of this combined immunosuppressive approach in larger patient populations.
Clinical Implications
Clinicians should be vigilant for signs of AIHA in patients receiving ICIs, particularly when symptoms of anemia arise. The combination of cyclophosphamide and fluorouracil with corticosteroids may offer a viable treatment strategy for severe cases of AIHA, allowing for the continuation of effective cancer therapies.
Conclusion
This case underscores the importance of recognizing and managing severe AIHA as a potential complication of pembrolizumab therapy. With appropriate interventions, safe rechallenge with ICIs may be achievable in select patients.
“We’ve made great strides treating melanoma at Fox Chase and have built one of the most comprehensive multidisciplinary teams in the region—an expertise recognized nationally and internationally,” says Jeffrey M. Farma, MD, FACS, Chair and Professor, Department of Surgery, Fox Chase Cancer Center. “I’m thrilled to bring TIL (tumor-infiltrating lymphocyte) therapy to our metastatic melanoma patients who are not responding to their first-line treatment—a cellular therapy which requires critical timing and a highly specialized multidisciplinary team to deliver it.”
